Drug Discovery unbound™

Propelled by our novel ACEAT™ technology, Xomics is charting towards a blue ocean of opportunities to develop protein therapeutics targeting complex membrane-bound proteins, which account for nearly 40% of the druggable human genome.   

Please contact us for more information.